Caprock Group’s Exact Sciences EXAS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-3,187
Closed -$324K 1160
2025
Q4
$324K Buy
+3,187
New +$256K 0.01% 970
2023
Q3
Sell
-2,227
Closed -$209K 668
2023
Q2
$209K Buy
+2,227
New +$174K 0.02% 606
2021
Q3
Sell
-2,638
Closed -$328K 553
2021
Q2
$328K Buy
2,638
+230
+10% +$27.4K 0.03% 341
2021
Q1
$317K Buy
2,408
+70
+3% +$9.58K 0.03% 319
2020
Q4
$310K Buy
2,338
+52
+2% +$6.29K 0.04% 317
2020
Q3
$233K Sell
2,286
-12
-0.5% -$1.04K 0.03% 339
2020
Q2
$200K Buy
+2,298
New +$184K 0.03% 369
2018
Q2
Sell
-6,360
Closed -$256K 459
2018
Q1
$256K Buy
+6,360
New +$310K 0.05% 318

Other funds holding EXAS

Caprock Group's EXAS Position: Q1 2026 in Review

Caprock Group sold out of Exact Sciences (EXAS) in Q1 2026, closing a stake of 3,187 shares — an estimated $324K sold.

Caprock Group first reported a position in EXAS in Q1 2018 and held it in 8 quarters. The position peaked at $328K in Q2 2021. 7 funds tracked by Wall St. Rank hold EXAS as of Q1 2026.

  • Caprock Group reported no remaining Exact Sciences position as of Q1 2026 after selling out during the quarter.
  • Caprock Group sold 3,187 Exact Sciences shares in Q1 2026, an estimated $324K.
  • Caprock Group first reported a position in Exact Sciences in Q1 2018 and held it in 8 quarters.
  • Caprock Group's Exact Sciences position peaked at $328K in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2026.

Based on Caprock Group's 13F filing for Q1 2026, filed 11 May 2026.